Home
|
Inbox
|
Search
|
View Abstract
Use of Omalizumab in Mexican Patients with a Diagnosis of Moderate to Severe Non-Atopic Asthma: An Observational Study
Description
.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px } .abstract { overflow-x:scroll } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px } .abstract td, th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; } .abstract a { overflow-wrap: break-word; word-wrap: break-word; }
A1391 - Use of Omalizumab in Mexican Patients with a Diagnosis of Moderate to Severe Non-Atopic Asthma: An Observational Study
Author Block: J. Herrera; ASMA CLINIC, University Hospital of Puebla Mexico, Puebla, Mexico.
INTRODUCTION While up to 50% of patients with severe asthma have no evidence of allergy, IgE has been linked to asthma, regardless of the atopic state. It has been reported that omalizumab, an anti-IgE monoclonal antibody, significantly benefits a subset of patients with severe and persistent allergic asthma. Therefore, we investigated whether omalizumab has biological and clinical effects in patients with non-atopic refractory asthma. METHODS: 20 Adult patients who despite daily treatment with or without maintenance oral corticosteroids had severe, non-atopic refractory asthma according to GINA (Global Initiative for Asthma) step 4 were assigned to receive omalizumab at doses of IgE levels (150 Mg SC each month) The primary end point was the change in clinical and functional parameters of patients through ACT (Asthma Control Test). RESULTS: After 52 weeks of administration of Omalizumab showed an overall increase in FEV1 and clinical and functional parameters. Symptomatic improvement of patients with ACT increase of 9 to 20 points. There was also good tolerance to the drug, with no serious adverse effect and improvement in asthma exacerbation in all patients. CONCLUSIONS Omalizumab negatively regulates FcεRI expression in patients with severe non-atopic asthma, as in severe atopic asthma. Omalizumab has a therapeutic role in severe non-atopic asthma. Our findings support the clinical efficacy of omalizumab in Mexican non-atopic asthmatic patients.
Author Block: J. Herrera; ASMA CLINIC, University Hospital of Puebla Mexico, Puebla, Mexico.
INTRODUCTION While up to 50% of patients with severe asthma have no evidence of allergy, IgE has been linked to asthma, regardless of the atopic state. It has been reported that omalizumab, an anti-IgE monoclonal antibody, significantly benefits a subset of patients with severe and persistent allergic asthma. Therefore, we investigated whether omalizumab has biological and clinical effects in patients with non-atopic refractory asthma. METHODS: 20 Adult patients who despite daily treatment with or without maintenance oral corticosteroids had severe, non-atopic refractory asthma according to GINA (Global Initiative for Asthma) step 4 were assigned to receive omalizumab at doses of IgE levels (150 Mg SC each month) The primary end point was the change in clinical and functional parameters of patients through ACT (Asthma Control Test). RESULTS: After 52 weeks of administration of Omalizumab showed an overall increase in FEV1 and clinical and functional parameters. Symptomatic improvement of patients with ACT increase of 9 to 20 points. There was also good tolerance to the drug, with no serious adverse effect and improvement in asthma exacerbation in all patients. CONCLUSIONS Omalizumab negatively regulates FcεRI expression in patients with severe non-atopic asthma, as in severe atopic asthma. Omalizumab has a therapeutic role in severe non-atopic asthma. Our findings support the clinical efficacy of omalizumab in Mexican non-atopic asthmatic patients.
|
Home
|
Inbox
|
Search
|